Published on 08 May 2012
Nomenclature for biosimilars; a continuing thorny issue
Author(s): Robin Thorpe, PhD, FRCPath
biosimilars, INN, nomenclature, US Food and Drug Administration (FDA)
DOI: 10.5639/gabij.2018.0704.029
6.105 views
Published on 08 May 2012
Author(s): Robin Thorpe, PhD, FRCPath
biosimilars, INN, nomenclature, US Food and Drug Administration (FDA)
DOI: 10.5639/gabij.2018.0704.029
6.105 views
Published on 08 October 2020
Author(s): Professor Alain Astier, PharmD, PhD
DOI: 10.5639/gabij.2020.0904.024
6.030 views
Published on 30 August 2021
biologicals, biosimilars, dermatology, psoriasis
DOI: 10.5639/gabij.2021.1003.018
5.951 views
Published on 23 September 2014
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2014.0304.049
5.947 views
Published on 14 February 2012
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2012.0101.001
5.929 views
Published on 07 May 2024
affordability, biosimilars, low- and middle-income countries (LMICs), market access, non-communicable diseases, regulatory framework
DOI: 10.5639/gabij.2024.1302.008
5.913 views
Published on 16 December 2015
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0501.011
5.826 views
Published on 20 February 2015
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2015.0401.012
5.808 views
Published on 04 May 2023
biologicals, biosimilars, Canada, ophthalmology
DOI: 10.5639/gabij.2023.1202.008
5.676 views
Published on 28 January 2022
biosimilars, biotherapeutics, monographs, pharmacopoeia, public standards
DOI: 10.5639/gabij.2022.1101.003
5.626 views
Published on 29 June 2012
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2012.0102.013
5.560 views
Published on 15 June 2015
Author(s): Meenu Wadhwa, PhD, Robin Thorpe, PhD, FRCPath
DOI: 10.5639/gabij.2015.0403.024
5.558 views